Table 1.
Demographic information.
| Demographics | NIH, n = 35 | NYU, n = 77 | Istanbul, n = 107 | ANOVA p |
|---|---|---|---|---|
| Age, yrs, mean (SD) | 36.1 (± 13.4) | 36.8 (± 13.5) | 37.4 (± 11.9) | 0.85 |
| Men, n (%) | 7 (20) | 6 (7.8) | 42 (39.3) | < 0.001* |
| Disease duration, yrs, mean (SD) | 10.7 (± 11.5) | 8.5 (± 5.7) | 6.9 (± 6.2) | 0.02* |
| Medications, n (%) | ||||
| Colchicine | 8 (22.9) | 16 (20.8) | 51 (47.7) | < 0.001* |
| Prednisone | 17 (48.6) | 37 (48.1) | 11 (10.3) | < 0.001* |
| Disease-modifying antirheumatic drugs | 20 (57.1) | 43 (55.8) | 46 (43) | 0.15 |
| Prior organ manifestations, n (%) | ||||
| Oral ulcers | 35 (100) | 71 (93.4) | 107 (100) | 0.008* |
| Genital ulcers | 31 (88.6) | 59 (78.7) | 86 (80.4) | 0.45 |
| Arthralgia | 30 (85.7) | 59 (77.6) | 79 (73.8) | 0.35 |
| Skin disease | 32 (91.4) | 63 (84) | 99 (92.5) | 0.17 |
| Thrombosis | 8 (22.9) | 8 (10.7) | 13 (12.1) | 0.19 |
| Eye disease | 14 (40) | 30 (42.2) | 37 (34.6) | 0.57 |
| Gastrointestinal disease | 15 (42.9) | 27 (37) | 0 (0) | < 0.001* |
| Neurologic disease | 7 (20) | 13 (17.3) | 4 (3.7) | 0.003* |
*
Statistically significant. Study sites: NIH: US National Institutes of Health; NYU: New York University; Istanbul: University of Istanbul.